Editas Medicine EDIT
Editas Medicine FY 2020: revenue $90.7M; diluted EPS −$1.98
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-21-001915
- Document
- 10-K
- Exhibit 10.13
- Material contract
- Exhibit 10.14
- Material contract
- Exhibit 10.18
- Material contract
- Exhibit 10.24
- Material contract
- Exhibit 10.25
- Material contract
- Exhibit 10.32
- Material contract
Key figures from this report
These are the numbers Editas Medicine reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$90.7MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$116.0MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$1.98No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$139.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$179.8MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Merus MRUS
- Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
- Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
- Rezolute RZLT public float $204M, Dec 31, 2025
- Cardiff Oncology CRDF public float $205M, Jun 30, 2025